ArticleMedical oncology (Northwood, London, England)2011
Relationship of survivin to clinical drug resistance in Burkitt's lymphoma of the head and neck region.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma.BMC veterinary research · 2020Article
- Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells.BMC complementary medicine and therapies · 2020Article
- Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K⁺ channels.Molecular medicine reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to determine the potential role of survivin in the pathogenesis of Burkitt´s lymphoma (BL) and analyzing the relationship of its expression with response to therapy. The expression of survivin was investigated in seven archival tumor tissues of BL using the streptavidin-biotin complex technique. Immunohistochemical analysis showed that survivin expression was positive in 6 of 7 BL cases (85.7%). BL group with high survivin expression had poor response to chemotherapy than the group with low survivin expression (P=0.005). The results suggest that apoptosis inhibition by survivin is a significant prognostic parameter of poor response to chemotherapy in Burkitt's lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.